Teplizumab

Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes[1][2].

Product Specifications

CAS Number

[876387-05-2]

Product Name Alternative

MGA-031; PRV-031

UNSPSC

12352203

Target

CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/teplizumab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Teplizumab]

Molecular Weight

(150 kDa)

References & Citations

[1]Kevan C Herold, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381 (7) :603-613. |[2]Frank Waldron-Lynch, et al. I Analysis of FcR non-binding anti-CD3 mAb in humanized mice identifies novel human gut tropic cells with regulatory function that are found in patients. Sci Transl Med. 2012 Jan 25;4 (118) :118ra12. |[3]Brygida Bisikirska, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct;115 (10) :2904-13.